Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 13/20 | 0.43 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5868019 | 0.87 | PYGL (0.43) | PYGLCYP51A1HRH4HRH3SMYD3 | |
| SCHEMBL5868158 | 0.87 | PYGL (0.44) | PYGLHRH4SMYD3 | |
| Trifluoroacetic Acid SCHEMBL5867893 | 0.86 | PYGL (0.44) | PYGLCYP51A1SMYD3 | |
| SCHEMBL5868431 | 0.77 | PYGL (0.47) | PYGLHRH4SMYD3 | |
| Hydrochloric Acid SCHEMBL5868302 | 0.77 | PYGL (0.41) | PYGLHRH4 | |
| SCHEMBL7254522 | 0.77 | HRH4 (0.47) | PYGLHRH4HRH3SMYD3 | |
| SCHEMBL6175005 | 0.77 | ACHE (0.45) | HRH3RAB9A | |
| SCHEMBL5868163 | 0.74 | PYGL (0.47) | PYGLHRH4 | |
| SCHEMBL6987333 | 0.74 | PYGL (0.42) | PYGLHRH4HRH3SMYD3 | |
| Trifluoroacetic Acid SCHEMBL5868250 | 0.74 | HRH4 (0.43) | PYGLCYP51A1HRH4HRH3SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053078-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1289954-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6900196-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040259868-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-23 | — | — | US | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | PYGL 217/4885CYP51A1 1522/4885HRH4 3847/4885 |
| US-20040259868-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | PYGL 239/4885CYP51A1 772/4885HRH4 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.